B. Braun
B. Braun is a German, family-owned healthcare company specializing in medical devices, pharmaceuticals, surgical technology, infusion therapy, and renal care.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
B. Braun is a German medical technology and pharmaceutical company headquartered in Melsungen, Hesse. The business traces its origins to a pharmacy established there in 1839, which initially sold medicinal herbs by mail. Over time, the enterprise developed from a local pharmacy into a vertically integrated healthcare manufacturer serving hospitals, outpatient providers, surgeons, dialysis centers, and home-care patients. The company’s portfolio spans infusion and injection therapy, clinical nutrition, hospital consumables, surgical instruments, implants, wound care, anesthesia, infection prevention, extracorporeal blood treatment, and selected pharmaceutical products. Its principal operating areas include Hospital Care, Aesculap, Out Patient Market, B. Braun Avitum, and home-healthcare and sterilization services in selected markets. B. Braun states that it offers more than 5,000 healthcare products and manufactures the large majority of them itself, giving the group substantial control over product development, production, and supply chains. A major turning point came with the company’s move into industrial medical manufacturing, including surgical sutures and later intravenous solutions and hospital equipment. In 1956, B. Braun developed an early plastic container for intravenous solutions, supporting the wider adoption of disposable and polymer-based medical products. During the 1960s, the group became particularly associated with plastics for pharmaceutical and clinical applications. Its subsequent international expansion added production and commercial operations across Europe, North America, Latin America, and Asia. The acquisition and integration of Aesculap substantially broadened B. Braun’s position in surgery. Aesculap contributes surgical instruments, implants, sutures, electrosurgical equipment, powered systems, and professional education through the Aesculap Academy. B. Braun also operates in renal care through B. Braun Avitum, including products and services for extracorporeal blood treatment and dialysis. The company remains family-owned rather than publicly traded. Its scale has grown to tens of thousands of employees and facilities in more than 60 countries. B. Braun’s stated business model emphasizes long-term ownership, internal manufacturing expertise, clinical partnerships, and product systems designed for hospitals and other healthcare institutions. The group has also faced significant historical controversy, especially concerning the Lyodura dura-mater graft product, which was associated with transmission of Creutzfeldt–Jakob disease. In the United States, a subsidiary paid a civil settlement in 2010 concerning alleged overbilling of Medicaid. More recently, the company has been criticized for continuing operations in Russia after the invasion of Ukraine.
History
B. Braun began in 1839 as a pharmacy in Melsungen, Germany. Its early business included the sale and mail-order distribution of medicinal herbs. The company later established manufacturing operations and moved into medical products, initially gaining hospital business through surgical sutures. This manufacturing orientation became the foundation for a broader healthcare portfolio. During the twentieth century, B. Braun expanded from sutures into intravenous solutions, injection products, monitoring equipment, and other hospital technologies. In 1956, it developed a plastic container for intravenous solutions. The company’s work with plastics became particularly important during the 1960s, when polymer materials were increasingly adopted for pharmaceutical packaging and disposable medical products. This helped B. Braun build expertise across product design, materials, production, and clinical use. The group expanded internationally through new facilities and acquisitions in Europe, the United States, Brazil, Malaysia, and other markets. A major strategic addition was Aesculap, a German surgical-equipment manufacturer founded in Tuttlingen in 1867 by Gottfried Jetter. Aesculap became part of the B. Braun Group in 1998 and provided surgical instruments, implants, sutures, electrosurgical systems, powered equipment, and professional training. Its American subsidiary, Aesculap, Inc., had been established in 1977. B. Braun subsequently organized its activities into several divisions. Hospital Care covers infusion, injection, and disposable hospital products. Aesculap focuses on surgical technology. The Out Patient Market division serves care outside acute hospitals. B. Braun Avitum covers extracorporeal blood treatment and renal care. Other group activities include TransCare home healthcare services in Germany, Austria, and the United Kingdom, and B. Braun Sterilog, which provides surgical-instrument cleaning, decontamination, and sterilization services in the United Kingdom. The company also pursued activities beyond direct product manufacturing. In 2012 it entered genetic diagnostics through a participation in CeGaT, a company based in Tübingen. From 2012 to 2013, B. Braun increased its stake in Rhön-Klinikum as part of an effort to secure a minority blocking position. It opposed a proposed takeover by Fresenius together with Asklepios Kliniken and later challenged the sale of most of Rhön-Klinikum’s hospitals in court. After the transaction was completed, B. Braun reduced its holding. In 2013, it opened a day and seminar center at the Haydau monastery complex in Morschen. The group has also had a difficult legacy involving Lyodura, a dura-mater graft introduced in 1969 for neurosurgical use. The product was made from human donor tissue and was linked to transmission of Creutzfeldt–Jakob disease. Reports described failures in donor-history controls and alleged use of tissue from black-market cadavers. At least 154 cases of CJD have been associated with Lyodura in accounts cited by reference material. In 2002, B. Braun Melsungen agreed with Japanese health authorities to compensate affected families. In the twenty-first century, B. Braun has remained a large privately held healthcare group under Braun family ownership. It continues to manufacture medical devices, pharmaceuticals, surgical products, and renal-care systems, while operating sales, service, and production networks across more than 60 countries. Its international scale and family ownership distinguish it from many publicly traded competitors, although its operations and market presence have also generated scrutiny over historical product safety, healthcare billing, and continued activity in Russia.
- 2018
Dialyzer facility opens in Wilsdruff
[3]B. Braun opens a dialyzer production facility in Wilsdruff, Saxony.
- 2017
Alliance with Philips
[3]B. Braun and Philips announce an alliance for ultrasound-guided regional anesthesia.
- 2013
Haydau day and seminar center opens
[1]The company opens a day and seminar center in the Haydau monastery complex in Morschen.
- 2012
Expansion into genetic diagnostics
[1]B. Braun enters genetic diagnostics through a participation in Tübingen-based CeGaT.
- 2009
Named a leading German workplace
[1]B. Braun is reported as being named Germany’s best company to work for in a workplace-ranking context.
- 2002
Compensation agreement related to Lyodura
[1]B. Braun Melsungen agrees with Japanese health authorities to compensate families of victims associated with Lyodura-related CJD cases.
- 1998
Aesculap joins the B. Braun Group
[1]Aesculap AG is incorporated into B. Braun, substantially expanding the group’s surgical-technology activities.
- 1969
Lyodura introduced
[1]B. Braun launches Lyodura, a human dura-mater graft product later associated with transmission of Creutzfeldt–Jakob disease.
- 1956
Plastic intravenous-solution container developed
[1]B. Braun develops an early plastic container for intravenous solutions, supporting the company’s expansion in disposable hospital products.
- 1867
Aesculap is established
[6]Gottfried Jetter establishes Aesculap in Tuttlingen, creating the surgical-equipment business later integrated into B. Braun.
Products and positioning
A vertically integrated, family-owned healthcare technology group positioned around clinical reliability, integrated hospital workflows, in-house manufacturing, surgical expertise, and long-term partnerships with healthcare providers.
Infusion, injection, and hospital consumables
Hospital Care
B. Braun’s Hospital Care portfolio covers products used to prepare, administer, and monitor medication and fluids in clinical settings. It includes infusion solutions, infusion sets, injection products, pumps, medication-management systems, clinical nutrition, anesthesia-related products, and other disposable supplies. The division is aimed primarily at hospitals and healthcare professionals seeking integrated systems for safe medication delivery and routine patient care.
Surgical technology · 1867
Aesculap
Aesculap is B. Braun’s surgical-technology division. Its products include handheld surgical instruments, sutures, implants, electrosurgical devices, and powered surgical systems. The division serves hospitals and operating rooms and is supported by training and professional education through the Aesculap Academy. Aesculap’s integration gave B. Braun a major platform in surgery in addition to its established infusion and hospital-care businesses.
Renal care and extracorporeal blood treatment
B. Braun Avitum
B. Braun Avitum supplies products and services for extracorporeal blood treatment, including dialysis equipment, dialyzers, bloodlines, and related clinical systems. Its activities address renal-care providers and dialysis patients, extending B. Braun’s hospital portfolio into a specialized area requiring recurring consumables, equipment, and technical support.
Home healthcare
TransCare
TransCare is a B. Braun home-healthcare service operating in Germany, Austria, and the United Kingdom. It supports selected forms of care outside the hospital environment and reflects the group’s broader interest in continuing treatment across hospital, outpatient, and home settings.
Instrument reprocessing services
B. Braun Sterilog
B. Braun Sterilog provides cleaning, decontamination, and sterilization services for surgical instruments in the United Kingdom. The referenced facilities are located in Pudsey, Yardley Green, and King’s Norton. The service complements B. Braun’s surgical-equipment activities by addressing the maintenance and reprocessing of instruments after use.
Neurosurgical graft · 1969
Lyodura
Lyodura was a human dura-mater graft introduced for neurosurgical use in 1969. The product was associated with transmission of Creutzfeldt–Jakob disease, an invariably fatal neurodegenerative illness. Its history became one of the most serious controversies connected with B. Braun and its predecessor operations.
Controversies
2022
Continued Russian operations after the invasion of Ukraine
B. Braun has faced criticism for maintaining business activities in Russia after the invasion of Ukraine. The Leave Russia project reported Russian subsidiary revenue and employment figures for 2021 and characterized the company as continuing operations rather than exiting the market.
2010
US Medicaid overbilling settlement
B. Braun Medical agreed to pay $14.7 million to resolve allegations that the US Medicaid program had paid inflated amounts for dozens of products. The settlement involved a B. Braun subsidiary and concerned government healthcare reimbursement.
1969
Lyodura and Creutzfeldt–Jakob disease transmission
Lyodura, a dura-mater graft used in neurosurgery, was linked to transmission of Creutzfeldt–Jakob disease. Accounts cited in the reference material report inadequate donor histories, including tissue allegedly obtained through black-market cadavers, and associate at least 154 diagnosed cases with the product. In 2002, B. Braun agreed with Japanese health authorities to compensate affected families.
Brand decisions
2018
Expand dialyzer manufacturing in GermanyStrategyBackground
Renal care and extracorporeal blood treatment are core B. Braun activities requiring specialized manufacturing capacity.
Action taken
B. Braun opened a new dialyzer production facility in Wilsdruff, Saxony.
Aftermath
The facility increased the group’s production footprint for dialysis products.
2017
Partner with Philips on regional anesthesiaOtherBackground
Ultrasound guidance was becoming increasingly important in regional anesthesia and nerve-block procedures.
Action taken
B. Braun and Philips formed an alliance combining ultrasound technology with B. Braun’s anesthesia-related products and expertise.
Aftermath
The alliance expanded the companies’ offering for ultrasound-guided regional anesthesia; the reference material provides no later commercial figures.
2012
Enter genetic diagnostics through CeGaT participationStrategyBackground
B. Braun sought to broaden its healthcare-technology activities beyond established medical devices, pharmaceuticals, and hospital supplies.
Action taken
The company took a participation in Tübingen-based genetic-diagnostics company CeGaT.
Aftermath
The move gave B. Braun exposure to genetic diagnostics, although the reference material does not specify the later financial or operational outcome.
2012
Build a blocking minority position in Rhön-KlinikumStrategyBackground
B. Braun sought influence over Rhön-Klinikum during a proposed takeover battle involving Fresenius.
Action taken
Between 2012 and 2013, B. Braun increased its stake from 5 percent to 18 percent and obtained antitrust approval to raise it to 25 percent.
Aftermath
Together with Asklepios Kliniken, B. Braun opposed the Fresenius takeover and later challenged the sale of most Rhön hospitals. After the sale was completed, B. Braun reduced its stake.
- Fresenius — Fresenius pursued the takeover of Rhön-Klinikum, which B. Braun opposed.
- Asklepios Kliniken — Asklepios joined B. Braun in opposing the proposed takeover.
Recent events
- 2018
B. Braun opens dialyzer production facility in Saxony[3]
Product generation · Other
The company opened a new production facility for dialyzers in Wilsdruff, Germany, strengthening its renal-care manufacturing capacity.
- 2017
B. Braun and Philips form an ultrasound-guided regional anesthesia alliance[3]
M&A · Product launch · Other
B. Braun and Philips announced a collaboration focused on ultrasound-guided regional anesthesia, combining Philips imaging technology with B. Braun anesthesia and injection expertise.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/b-braun · Editorial policy · How profiles are compiled